Rapid Dose Therapeutics Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark Andrew Upsdell
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1121 Walkers Line Burlington ON Canada L7N 2G4
- IPO Date
- Sep 27, 2019
- Website
- rapid-dose.com
- Similar Companies
- Business
- Rapid Dose Therapeutics Corp. (CSE: DOSE; OTC: RDTCF) develops and commercializes innovative oral thin film drug delivery technologies, primarily through its proprietary QuickStrip platform, which provides rapid sublingual dissolution for pharmaceuticals, nutraceuticals, over-the-counter medications, and cannabinoids. The company offers QuickStrip and PharmaStrip products encompassing nutraceutical formulations such as energy strips with caffeine, vitamin B12 strips for metabolism support, sleep strips with melatonin, and lidocaine strips for dental applications; pharmaceutical delivery solutions including nicotine strips under the NicStrip brand in 1mg, 3mg, and 4mg doses; cannabis-infused strips; and customized white-label oral thin films for active ingredients like micronized oils, vaccines, and opioids; alongside product innovation, production services, consultation, and licensing agreements for the healthcare, pharmaceutical, nutraceutical, and cannabis industries. Founded in 2017 and headquartered in Burlington, Ontario, Canada, Rapid Dose Therapeutics operates primarily in North America with distribution partnerships extending to the United States and India, targeting consumer retail channels including over 378 Circle K locations, grocery stores, airport retailers, and e-commerce platforms; its business segments include health and wellness nutraceuticals, white-label cannabis products, and managed service sales agreements for recurring revenue. Recent developments encompass a seven-month extension in October 2025 of its exclusive pre-commercialization agreement with an unnamed international nicotine partner, valued at up to $1.8 million CAD to advance NicStrip commercialization, including ongoing pharmacokinetic studies and two international PCT patent applications filed in May 2025; a July 2025 Health Canada-funded harm reduction pilot project with Eco Canadian Organic Inc. deploying QuickStrip technology to combat opioid addiction in First Nations communities; an August 2025 Health Canada submission for NicStrip nicotine products; a three-year distribution agreement with Perennial Brands for nutraceutical strips in Canada, the US, and India; and various debt settlements, share issuances for interest payments, and a proposed $3 million equity private placement in May 2025 to support operational expansion.
Rapid Dose Therapeutics Extends Strategic Collaboration with Global Nicotine Leader and Initiating Saudi Arabia Commercialization
Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market
Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform
Rapid Dose Therapeutics Begins Trading on the OTCQB in the United States Under Symbol RDTCF, Expanding Access for U.S. Healthcare and Biotechnology Investors
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Rapid Dose Completes Extension to Promissory Notes
Rapid Dose Announces Extension to Promissory Notes
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt